Dr Reddy’s Laboratories has acquired the trademarks for Progynova and Cyclo-Progynova from UK-headquartered Mercury Pharma Group for $32.15 million, marking its entry into the hormone replacement therapy (HRT) segment. This acquisition strengthens Dr Reddy’s gynaecology portfolio in India. The brands recorded sales of Rs 100 crore as per IQVIA MAT December 2025.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dr Reddy's enters hormone replacement therapy segment with $32 mn buy
Dr Reddy’s Laboratories has acquired the trademarks for Progynova and Cyclo-Progynova from UK-headquartered Mercury Pharma Group for $32.15 million, marking its entry into the hormone replacement therapy (HRT) segment. This acquisition strengthens Dr Reddy’s gynaecology portfolio in India. The brands recorded sales of Rs 100 crore as per IQVIA MAT December 2025.